ARCT Q3 2021 Earnings — Arcturus Therapeutics Holdings Inc. Revenue & Financial Results | Market Cap Arena

ARCTArcturus Therapeutics Holdings Inc.

$210M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+4.5% YoY

Gross Profit

-$43M-1762.9% margin

Operating Income

-$54M-2208.5% margin

Net Income

-$54M-2219.3% margin

EPS (Diluted)

$-2.05

QoQ Revenue Growth

+21.8%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$18M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$435M

Total Liabilities

$175M

Stockholders' Equity

$259M

Cash & Equivalents

$414M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	+4.5%
Gross Profit	-$43M	$2M	-1941.4%
Operating Income	-$54M	-$21M	-157.0%
Net Income	-$54M	-$21M	-157.5%